Projects and Investigators

FY 2002 Projects

University of Rochester

Objective

Preclinical and clinical investigation of the safety and tolerability of a human papillomavirus virus-like particle vaccine.

Program Description

Investigators will conduct preclinical and clinical investigation of the safety and tolerability of a human papillomavirus virus-like particle vaccine co-administered in combination with E. coli heat-labile enterotoxin mutant R192G (LTR192G) by oral, intranasal, or transcutaneous routes of immunization. Certain human papillomaviruses cause cervical cancer, which remains a significant source of morbidity and mortality among women worldwide. This project proposes to study the safety and tolerability of a virus-like particle vaccine when co-administered with adjuvant E. coli LTR192G by three alternate routes of delivery (oral, intranasal, or transcutaneous). RAPID support will include production of HPV-16 L1 and E. coli LTR192G for preclinical testing.

Contact Information

Dr. Robert C. Rose
University of Rochester School of Medicine
Rochester, NY
Tel: 716-275-0263
Fax: 716-442-9328
E-mail: Robert_Rose@URMC.Rochester.edu